Skip to main content
. 2010 Dec 10;1(2):233–239.

Figure 4.

Figure 4

CDH22 expression is correlated to 5-year survival of all melanoma patients. (A) Patients with negative CDH22 staining have a worse overall 5-year survival than patients with positive CDH22 staining (P = 0.070). (B) Patients with negative CDH22 staining have a worse disease-specific 5-year survival than patients with positive CDH22 staining (P = 0.036).